ArticleClinical and translational science2026
Increased mROS Generation Associates With Cardiovascular Risk in BioHEART-CT PBMCs.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased mROS Generation Associates With Cardiovascular Risk in BioHEART-CT PBMCs.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, and identifying accessible blood-based biomarkers is therefore a clinical priority. Given the involvement of oxidative stress and immune cell dysfunction in atherosclerosis, we investigated whether mitochondrial reactive oxygen species (mROS) production in peripheral blood mononuclear cells (PBMCs) is associated with CAD. This exploratory study analyzed PBMCs from 40 BioHEART-CT participants with or without CT-defined CAD using MitoSOX-based flow cytometry. In parallel, single-cell RNA sequencing (scRNA-seq) was conducted in the same individuals to investigate differential expression of CCBE1, a recently implicated gene in cardiovascular disease, across PBMC populations. Overall, mROS levels in PBMCs and their major cellular subtypes did not show consistent or meaningful associations with CAD status or with modifiable cardiovascular risk factors. Small, subgroup-specific signals-such as moderate association between lymphocyte mROS and coronary artery calcium score in males, and a modest inverse association between monocyte mROS and hypertension-were exploratory and not uniform across analyses. scRNA-seq analysis did not identify a distinct CCBE1 expression signature in PBMCs. These findings indicate that PBMC-derived mROS is unlikely to serve as a useful cross-sectional biomarker of CAD in stable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.